Internal Medicine
RCT | Effect of lifestyle coaching or enhanced pharmacotherapy on blood pressure control among black adults with persistent uncontrolled hypertension.
5 Aug, 2022 | 13:52h | UTCCommentary: Lifestyle Coaching Intervention Improves BP Control Among Blacks – HealthDay
Commentary on Twitter
In this cluster randomized trial, a 1-year lifestyle coaching intervention (but not enhanced pharmacotherapy) was more effective than usual care in achieving blood pressure control at 2-4 years in Black adults with persistent uncontrolled hypertension. https://t.co/c7pZykQnFw
— JAMA Network Open (@JAMANetworkOpen) May 18, 2022
Enhancing primary stroke prevention: a combination approach.
4 Aug, 2022 | 14:42h | UTCEnhancing primary stroke prevention: a combination approach – The Lancet Public Health
Commentary on Twitter
Primary #stroke #prevention strategies target behavioural and pharmacological approaches. Also need to manage structural factors that support or hinder prevention actions and behaviours. @StrokeImperial @Simzy_x @Tsering_ @SomaBanerjee73 @CFCFoundation
https://t.co/vyyhhfeg7Y pic.twitter.com/kqwF9DROG2— Joseph Kwan, MD 🇬🇧 (@drjkwan) July 31, 2022
Under a Creative Commons Attribution (CC BY 4.0) license
Case-Control Study | Outpatient oral macrolide use is associated with increased risk of sensorineural hearing loss in children, adolescents, and young adults.
4 Aug, 2022 | 14:29h | UTCAssociation of Outpatient Oral Macrolide Use With Sensorineural Hearing Loss in Children, Adolescents, and Young Adults – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – $ for full-text)
Commentary: Kids’ Hearing Loss Associated With Common Antibiotics — Children and teens with sensorineural hearing loss more often macrolide users – MedPage Today (free registration required)
Cohort Study | The risk of opioid overdose is increased with concomitant use of oxycodone and selective serotonin reuptake inhibitors that are inhibitors of oxycodone metabolism.
4 Aug, 2022 | 14:27h | UTCCommentary from the author: Taking certain opioids while on commonly prescribed antidepressants may increase the risk of overdose – The Conversation
Commentary on Twitter
This cohort study found that concomitant use of oxycodone with potent CYP2D6-inhibiting serotonin reuptake inhibitors (SSRIs, eg. fluoxetine or paroxetine) is associated with an increased risk of overdose. https://t.co/Eol89RHWAu
— JAMA Network Open (@JAMANetworkOpen) February 24, 2022
In a cohort study with a median follow‐up of 23.2 years, both very low and very high LDL‐C levels are associated with increased risk of cardiovascular mortality in the general population.
4 Aug, 2022 | 14:25h | UTC
M-A | Efficacy of Doxycycline for mild-to-moderate community-acquired pneumonia in adults.
4 Aug, 2022 | 14:17h | UTCEfficacy of Doxycycline for Mild-to-moderate Community-acquired Pneumonia in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials – Clinical Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter
🆕⚡⚡Systematic Review and Meta-analysis of Randomized Controlled Trials @CIDJournal
Efficacy of Doxycycline for Mild-to-moderate CAP in Adults
The efficacy of doxycycline was comparable to macrolides or fluoroquinolones in mild-moderate CAP #IDTwitter https://t.co/L7UBBUc4Dm— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) July 29, 2022
Cohort Study | Bariatric surgery linked to doubling chance of marriage or divorce.
4 Aug, 2022 | 14:16h | UTCNews Release: Bariatric Surgery Linked to Doubling Chance of Marriage or Divorce – University of Pittsburgh
Commentary: Spouse Getting Weight Loss Surgery? Your Marriage Might Be in Trouble – HealthDay
Recommendations on controversial issues in diagnosis and management of hyponatremia.
4 Aug, 2022 | 14:07h | UTC
Review | Management of liver decompensation in advanced chronic liver disease: ascites, hyponatremia, and gastroesophageal variceal bleeding.
4 Aug, 2022 | 13:40h | UTCRelated: Overview of Complications in Cirrhosis – Journal of Clinical and Experimental Hepatology
Guideline | Preventing obesity in midlife women.
3 Aug, 2022 | 14:37h | UTCCommentary: Counseling Can Prevent Obesity in Normal, Overweight Women – HealthDay
Commentary on Twitter
New guidelines aim to prevent #obesity in midlife women. @TheWPSI recommends counseling to prevent weight gain in all women at normal or overweight BMI. Full text available at https://t.co/P8VwBWIHXe @CedarsSinai @acog pic.twitter.com/YxTQVgXj59
— Annals of Int Med (@AnnalsofIM) August 2, 2022
M-A | Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials.
3 Aug, 2022 | 14:31h | UTC
Antivirals with activity against Monkeypox: a clinically oriented review.
3 Aug, 2022 | 14:26h | UTCRelated:
WHO chief advises men who have sex with men to reduce partners to limit exposure to monkeypox – CNN
WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch
Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases
Review | Diagnosis, treatment, and prevention of Malaria in the US.
3 Aug, 2022 | 14:27h | UTCDiagnosis, Treatment, and Prevention of Malaria in the US: A Review – JAMA (free for a limited period)
Audio Clinical Review: Diagnosis, Treatment, and Prevention of Malaria in the US – JAMA
Cohort Study | Association between gout flare and subsequent cardiovascular events among patients with gout.
3 Aug, 2022 | 14:30h | UTCAssociation Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout – JAMA (free for a limited period)
Editorial: Cardiovascular Events and Gout Flares – JAMA (free for a limited period)
News Release: Flare-ups of gout are linked to heart attack and stroke – University of Nottingham
Commentary: Association Between Gout Flare and Subsequent Cardiovascular Events – American College of Cardiology
Cohort Study | Association of higher-dose fluoroquinolone therapy with serious adverse events in older adults with advanced chronic kidney disease.
3 Aug, 2022 | 14:22h | UTC
Evidence Synthesis | Deprescribing medicines in older people living with multimorbidity and polypharmacy.
3 Aug, 2022 | 14:20h | UTCRelated:
Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports
Deprescribing in Palliative Cancer Care – Life
Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360
Polypharmacy Management in Older Patients – Mayo Clinic Proceedings
Eliminating Medication Overload: A National Action Plan – Lown Institute
Common ED Medication Errors: Polypharmacy – emDocs
Current and future perspectives on the management of polypharmacy – BMC Family Practice
Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international
Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety
Guideline | Male lower urinary tract symptoms/benign prostatic hyperplasia.
3 Aug, 2022 | 14:17h | UTCRelated:
Podcast: LUTS, BPH, and Urinary Incontinence Triple Distilled – The Curbsiders
Guideline | Androgen deprivation therapy: adverse events and management strategies.
3 Aug, 2022 | 14:15h | UTC
RCT | Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction.
3 Aug, 2022 | 14:06h | UTC
Commentary on Twitter
No one wants to add meds just so you can add more meds. BUT, adding patiromer in select patients with HFrEF so you can optimize GDMT sure is compelling… 🤔 https://t.co/79gSEwon4y
— ATRIUM Cardiology (@ATRIUMRx) July 29, 2022
Review | Management of alcohol-related liver disease and its complications.
3 Aug, 2022 | 13:56h | UTCManagement of Alcohol-Related Liver Disease and Its Complications – Clinical Drug Investigation
Related Guideline: Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines – Liver International
Commentary on Twitter (thread – click for more)
Excellent review about the Management of Alcohol-Related Liver Disease and Its Complications carried out by Dr. Cabezas.https://t.co/VICukJ3jEt
Key points:
1. It is still a stigmatized condition with underlying pathology.@AEEHLiver @sepdigestiva #LiverTwitter …— Javier Crespo (@DrJavierCrespo) July 29, 2022
WHO Guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations.
2 Aug, 2022 | 12:41h | UTCNews Release: WHO publishes new guidelines on HIV, hepatitis and STIs for key populations – World Health Organization
Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019.
2 Aug, 2022 | 12:37h | UTCNews Release: Chronic lung disease remains major public health problem – BMJ Newsroom
Commentary on Twitter
New research finds that despite the decreasing burden of COPD, this disease remains a major public health problem, especially in countries with a low sociodemographic index https://t.co/uUkQYCSmBY
— The BMJ (@bmj_latest) July 30, 2022
M-A | GLP1 receptor agonists are associated with increased risk of progression of retinopathy in patients with type 2 diabetes.
2 Aug, 2022 | 12:32h | UTCProgression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis – Journal of Diabetes and its Complications (link to abstract – $ for full-text)
Commentary: GLP1 RA use tied to increased risk of rapidly worsening retinopathy in type 2 diabetes – Medical Dialogues
Retrospective Cohort Study | Syncope and the risk of subsequent motor vehicle crash.
2 Aug, 2022 | 12:33h | UTCSyncope and the Risk of Subsequent Motor Vehicle Crash: A Population-Based Retrospective Cohort Study – JAMA Internal Medicine (free for a limited period)
Editorial: Driving Safety After an Acute Illness—This Is Our Lane – JAMA Internal Medicine (free for a limited period)
Commentary on Twitter
"I fainted…am I safe to drive?" Study found that 9,223 drivers with an ED visit for syncope had subsequent crash risks no different than controls, suggesting more stringent driving restrictions might not be justified. https://t.co/T0GUJ63Nci
— JAMA Internal Medicine (@JAMAInternalMed) August 1, 2022
RCT | Safety and efficacy of Tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan.
2 Aug, 2022 | 12:05h | UTCSafety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
See also (note: the dulaglutide dosage used in this trial was probably suboptimal): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Related:
Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022